Physician profile
Michael Gitelis
NPI 1366550402
$1,319.41
in general payments reported to CMS, 2019-2025
13 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.99 · 2022: $29.75 · 2023: $383 · 2024: $598 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $312.96 | 2024-2025 | Prolate, Nalocet, Tanlor |
| Smith+Nephew, INC. | $228.13 | 2023-2025 | Lens, N/A, Healicoil |
| Stryker Corporation | $176.93 | 2021-2023 | Inspace |
| Abbott Laboratories | $152.00 | 2024 | Proclaim |
| Sonex Health, INC. | $110.63 | 2025 | Sx-One Microknife |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.35 | 2023 | Relistor |
| Radius Health, INC. | $81.08 | 2024 | Tymlos |
| Protega Pharmaceutials INC | $75.92 | 2024-2025 | Roxybond |
| Innovation Technologies INC | $30.35 | 2024 | Irrisept |
| Goode Surgical INC | $23.14 | 2024 | |
| Medtronic, INC. | $17.50 | 2023 | Intellis Adaptivestim |
| Ibsa Pharma INC. | $16.42 | 2024 | Flector, Licart, Tirosint |
| Avanos Medical | $13.00 | 2023 | Trivisc Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gitelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.